SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006

Sitagliptin / Metformin Extended Release Formulation

Version 2.7 Revision Date: 27.08.2021 SDS Number: 29103-00019 Date of last issue: 09.04.2021
Date of first issue: 07.11.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Sitagliptin / Metformin Extended Release Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD Piercetown A86 HD21 Dunboyne, Ireland
   Telephone : 908-740-4000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4 H302: Harmful if swallowed.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : !
   Signal word : Warning
   Hazard statements : H302 Harmful if swallowed.
   Precautionary statements : Prevention:
                              P264 Wash skin thoroughly after handling.
                              P270 Do not eat, drink or smoke when using this product.
   Response:
                              P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
Hazardous components which must be listed on the label:
metformin hydrochloride

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>metformin hydrochloride</td>
<td>1115-70-4</td>
<td>T</td>
<td>Acute Tox. 4; H302</td>
</tr>
<tr>
<td></td>
<td>214-230-6</td>
<td>T</td>
<td>Eye Irrit. 2; H319</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aider : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled:
- Remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact:
- Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact:
- If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed:
- Do not induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

### 4.2 Most important symptoms and effects, both acute and delayed

**Risks:**
- Harmful if swallowed.
- Contact with dust can cause mechanical irritation or drying of the skin.
- Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

**Treatment:**
- Treat symptomatically and supportively.

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

**Suitable extinguishing media:**
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media:**
- None known.

#### 5.2 Special hazards arising from the substance or mixture

**Specific hazards during firefighting:**
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

**Hazardous combustion products:**
- Carbon oxides
- Metal oxides
- Nitrogen oxides (NOx)
- Silicon oxides
5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Sitagliptin / Metformin Extended Release Formulation

Version 2.7
Revision Date: 27.08.2021
SDS Number: 29103-00019
Date of last issue: 09.04.2021
Date of first issue: 07.11.2014

Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>metformin hydrochloride</td>
<td>1115-70-4</td>
<td>TWA</td>
<td>1 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>OELV - 8 hrs (TWA)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>TWA</td>
<td>0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

**Engineering measures**
Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

- **Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

- **Hand protection**: Chemical-resistant gloves

- **Skin and body protection**: Work uniform or laboratory coat.

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

- **Filter type**: Particulates type (P)

### SECTION 9: Physical and chemical properties

**9.1 Information on basic physical and chemical properties**

- **Physical state**: powder
- **Colour**: blue green
- **Odour**: No data available
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Flash point**: Not applicable
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Sitagliptin / Metformin Extended Release Formulation

Version 2.7  Revision Date: 27.08.2021  SDS Number: 29103-00019  Date of last issue: 09.04.2021

Date of first issue: 07.11.2014

Auto-ignition temperature : No data available
Decomposition temperature : No data available
pH : No data available
Viscosity
  Viscosity, kinematic : Not applicable
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water
  : Not applicable
Vapour pressure : Not applicable
Relative density : No data available
Density : No data available
Relative vapour density : Not applicable
Particle characteristics
  Particle size : No data available

9.2 Other information
  Explosives : Not explosive
  Oxidizing properties : The substance or mixture is not classified as oxidizing.
  Evaporation rate : Not applicable
  Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
  Not classified as a reactivity hazard.

10.2 Chemical stability
  Stable under normal conditions.

10.3 Possibility of hazardous reactions
  Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
  Conditions to avoid : Heat, flames and sparks. Avoid dust formation.
10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 1,588 mg/kg
Method: Calculation method

Components:
metformin hydrochloride:
Acute oral toxicity: LD50 (Rat): 1,000 mg/kg
LD50 (Mouse): 1,450 - 3,500 mg/kg
LD50 (Monkey): 463 mg/kg
LD50 (Rabbit): 350 mg/kg
LD50 (Guinea pig): 500 mg/kg

Sitagliptin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
metformin hydrochloride:
Species: Rabbit
Result: Mild skin irritation
Sitagliptin / Metformin Extended Release Formulation

Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
metformin hydrochloride:
Species: Rabbit
Result: Mild eye irritation

Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: Irritating to eyes.

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Sitagliptin:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Method: OECD Test Guideline 429
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:
metformin hydrochloride:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: in vitro assay
Test system: mouse lymphoma cells
Result: negative
Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative
Sitagliptin / Metformin Extended Release Formulation

Genotoxicity in vivo:
- Test Type: Micronucleus test
  - Species: Mouse
  - Application Route: Oral
  - Result: negative

Genotoxicity in vitro:
- Test Type: Ames test
  - Result: negative

- Test Type: Chromosome aberration test in vitro
  - Test system: Chinese hamster ovary cells
  - Result: negative

- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Test system: rat hepatocytes
  - Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  - Species: Mouse
  - Application Route: Oral
  - Result: negative

Carcinogenicity
Not classified based on available information.

Components:

metformin hydrochloride:
- Species: Mouse
- Exposure time: 91 weeks
- Dose: 1500 mg/kg body weight
- Result: negative

- Species: Rat, male
  - Application Route: Oral
  - Exposure time: 104 weeks
  - Dose: 900 mg/kg body weight
  - Result: negative

- Species: Rat, female
  - Application Route: Oral
  - Exposure time: 104 weeks
  - LOAEL: 900 mg/kg body weight
  - Result: negative
  - Target Organs: Uterus (including cervix)
  - Remarks: The mechanism or mode of action may not be relevant in humans.
Sitagliptin / Metformin Extended Release Formulation

Sitagliptin:
Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Rat
Application Route: oral (drinking water)
Exposure time: 2 Years
Result: positive
Target Organs: Liver
Remarks: Significant toxicity observed in testing

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:
metformin hydrochloride:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 600 mg/kg body weight
Result: No effects on fertility

Effects on foetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 600 mg/kg body weight
Result: No teratogenic effects

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 140 mg/kg body weight
Result: No teratogenic effects

Sitagliptin:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL Parent: 1,000 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Teratogenicity: LOAEL: 250 mg/kg body weight
Sitagliptin / Metformin Extended Release Formulation

Result: Embryotoxic effects and adverse effects on the offspring were detected. No teratogenic effects

Test Type: Embryo-foetal development
Species: Rabbit
Teratogenicity: NOAEL: 125 mg/kg body weight
Result: No teratogenic effects

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

metformin hydrochloride:

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>125 mg/kg</td>
<td>Oral</td>
<td>1 year</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>100 mg/kg</td>
<td>Oral</td>
<td>1 Year</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>50 mg/kg</td>
<td>Subcutaneous</td>
<td>2 year</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

Sitagliptin:

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>500 mg/kg</td>
<td>1,000 mg/kg</td>
<td>Oral</td>
<td>&gt; 2 yr</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>500 mg/kg</td>
<td>1,000 mg/kg</td>
<td>Oral</td>
<td>14 Weeks</td>
<td>Liver, Kidney, Heart, Teeth</td>
</tr>
</tbody>
</table>
Species: Dog
NOAEL: 10 mg/kg
LOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Target Organs: Central nervous system
Symptoms: Loss of balance
Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Dog
NOAEL: 2 mg/kg
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 27 Weeks
Target Organs: Skeletal muscle, Central nervous system
Symptoms: Loss of balance
Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Monkey
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

metformin hydrochloride:
Skin contact: Remarks: May irritate skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Diarrhoea, Nausea, Vomiting, Gastrointestinal discomfort, flatulence, asthenia, Fatigue, Headache

Sitagliptin:
Inhalation: Symptoms: upper respiratory tract infection, pharyngitis, Headache
**Ingestion**

Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

### SECTION 12: Ecological information

#### 12.1 Toxicity

**Components:**

**metformin hydrochloride:**

- **Toxicity to algae/aquatic plants:**
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

  NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **Toxicity to microorganisms:**
  - EC50 : > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

- **Toxicity to fish (Chronic toxicity):**
  - NOEC: 10 mg/l
  - Exposure time: 33 d
  - Species: Pimephales promelas (fathead minnow)
  - Method: OECD Test Guideline 210

- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):**
  - NOEC: 40 mg/l
  - Exposure time: 21 d
  - Species: Daphnia magna (Water flea)
  - Method: OECD Test Guideline 211

**Sitagliptin:**

- **Toxicity to fish:**
  - LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203

- **Toxicity to daphnia and other aquatic invertebrates:**
  - EC50 (Daphnia magna (Water flea)): 60 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202

- **Toxicity to algae/aquatic plants:**
  - EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 201

  NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l
  - Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to microorganisms:
- EC50: > 150 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- Method: OECD Test Guideline 209

NOEC: 150 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity):
- NOEC: 9.2 mg/l
- Exposure time: 33 d
- Species: Pimephales promelas (fathead minnow)
- Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 9.8 mg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

metformin hydrochloride:
- Biodegradability: Result: rapidly degradable
- Biodegradation: 50 %
- Exposure time: 2 hrs

Sitagliptin:
- Biodegradability: Result: not rapidly degradable
- Biodegradation: 39.7 %
- Exposure time: 28 d
- Method: OECD Test Guideline 314

Stability in water:
- pH: 7
- Hydrolysis: 50 % (401 d)
- Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

metformin hydrochloride:
- Partition coefficient: n-octanol/water: log Pow: -2

Sitagliptin:
- Partition coefficient: n-octanol/water: log Pow: -0.03
12.4 Mobility in soil

Components:

**metformin hydrochloride:**
Distribution among environmental compartments: $\log K_{oc} = 4.3$
Method: OECD Test Guideline 106

**Sitagliptin:**
Distribution among environmental compartments: $\log K_{oc} = 4.37$

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

Not regulated as a dangerous good
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Sitagliptin / Metformin Extended Release Formulation

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Sitagliptin / Metformin Extended Release Formulation

Version 2.7
Revision Date: 27.08.2021
SDS Number: 29103-00019
Date of last issue: 09.04.2021
Date of first issue: 07.11.2014

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-statements
H302: Harmful if swallowed.
H319: Causes serious eye irritation.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Eye Irrit.: Eye irritation
IE OEL: Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA): Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxin; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GHS - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; IC50 - International Civil Aviation Organization; ICSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information
Sitagliptin / Metformin Extended Release Formulation

Version: 2.7  Revision Date: 27.08.2021  SDS Number: 29103-00019  Date of last issue: 09.04.2021

Date of first issue: 07.11.2014

Classification of the mixture:  Classification procedure:
Acute Tox. 4  H302  Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN